FRM
ENTA icon

Fox Run Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Fox Run Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,501
Closed -$250K – 1031
2026
Q1 		$250K Buy
20,501
+10,319
+101% +$138K 0.04% 685
2025
Q4 		$161K Buy
+10,182
New +$129K 0.02% 828
2016
Q3 		– Sell
-9,800
Closed -$216K – 537
2016
Q2 		$216K Sell
9,800
-1,000
-9% -$26.2K 0.1% 410
2016
Q1 		$317K Buy
+10,800
New +$301K 0.21% 209

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fox Run Management's ENTA Position: Q2 2026 in Review

Fox Run Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 20,501 shares — an estimated $250K sold.

Fox Run Management first reported a position in ENTA in Q1 2016 and held it in 4 quarters. The position peaked at $317K in Q1 2016. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Fox Run Management reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 20,501 Enanta Pharmaceuticals shares in Q2 2026, an estimated $250K.
  • Fox Run Management first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Fox Run Management's Enanta Pharmaceuticals position peaked at $317K in Q1 2016.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.